Clinicopathologic and Prognostic Differences Between LI-RADS M Targetoid and LI-RADS M Nontargetoid Observations: A
Indira Laothamatas1, Simon Gauvin1, Luke Ginocchio1
1Department of Radiology, NYU Langone Health, New York, New York, USA.
Background:
Liver Imaging Reporting and Data System M (LR-M) lesions may appear targetoid or nontargetoid, but their clinicopathologic and prognostic differences remain unclear.
Purpose:
To compare clinical, pathological, and prognostic features of targetoid and nontargetoid LR-M lesions on dynamic contrast enhanced-MRI (DCE-MRI).
Study Type:
Retrospective.
Subjects:
119 consecutive patients (82 male, mean age = 62.9 ± 10.3 years) with 119 LR-M observations (75 targetoid, 44 nontargetoid) and at least 2 years of follow-up.
Field Strength/Sequence:
1.5T and 3.0T; T2-weighted fast spin echo sequence, diffusion-weighted image, and dynamic T1-weighted-gradient-echo sequence using an extracellular contrast agent.
Assessment:
Three radiologists categorized lesions as targetoid or nontargetoid. Clinical, laboratory, imaging, and histopathologic data were collected.
Statistical Tests:
Group differences were evaluated using t-tests and chi-square/Fisher's exact tests. Survival outcomes were assessed using Kaplan-Meier method with log-rank test and Cox proportional hazards regression. Inverse probability of treatment weighting (IPTW) was applied before survival analysis. A p-value < 0.05 was considered significant.
Results:
The nontargetoid group had significantly higher serum AFP (6684.7 ± 15,988 vs. 194.9 ± 898.4 ng/mL), larger lesion size (9.10 ± 5.55 cm vs. 3.55 ± 2.96 cm), cirrhosis (95% vs. 76%), extrahepatic disease (50% vs. 19%), and malignancy (95% vs. 82%). Nontargetoid group showed significantly higher mortality (75% vs. 41%), progression (77% vs. 45%), shorter overall survival (477 ± 629 vs. 1226 ± 1147 days), and time-to-progression (333 vs. 1003 days). On multivariable analysis with Cox proportional hazards regression, targetoid morphology was significantly associated with improved overall survival (HR = 0.28) and progression-free survival (HR = 0.36), whereas histology was not significant (HCC vs. non-HCC).
Data Conclusion:
Targetoid morphology is significantly associated with improved survival and delayed progression, supporting its role as a prognostic imaging biomarker.
Evidence Level:
3.
Technical Efficacy:
Stage 5.
